stock-detail (RXDX)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

4/24/2017 12:19 pm

Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology

3/30/2017 11:00 am

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced data demonstrating the successful treatment with entrectinib – Ignyta’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions – of a patient with a primary brain tumor harboring an NTRK1 fusion.

Ignyta Announces Multiple Presentations at the 2017 AACR Annual Meeting

3/28/2017 08:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced three data presentations at the 2017 Annual Meeting of the American Association for Cancer Research in Washington, D.C.

Ignyta Announces Exploration of Strategic Options for Taladegib, Enabled by Amendment of Taladegib License Agreement with Lilly

3/23/2017 08:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that it is exploring strategic options for taladegib and has entered into an amended and restated license, development and commercialization agreement with Eli Lilly and Company for the taladegib oncology program.

IGNYTA, INC. Financials

3/18/2017 05:00 pm

Ignyta Announces Full Year 2016 Company Highlights and Financial Results

3/14/2017 08:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced company highlights and financial results for the full year ended December 31, 2016.

Angsana's RNA-based fusions cancer panel selected for Ignyta's STARTRK2 clinical trial in Asia-Pacific

3/3/2017 02:00 pm

[Marketwired] - Angsana Molecular & Diagnostics has announced today that it will be a partner molecular test laboratory for STARTRK-2 clinical trial sites in Asia working with Ignyta, Inc., , a biotechnology company focused ...

Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery

2/9/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced that updated results from two Phase 1 trials of entrectinib—the company’s investigational, orally available, CNS-active tyrosine kinase inhibitor targeting tumors that harbor TRK, ROS1 or ALK fusions—were published in the journal Cancer Discovery.

Ignyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

2/8/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the LEERINK Partners 6th Annual Global Healthcare Conference on Wednesday, February 15, 2017, at 11:30 a.m.

Ignyta to Present at 35th Annual J.P. Morgan Healthcare Conference

1/4/2017 12:00 pm

[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 35th Annual J.P.